Skip to content

Trial Summary

This phase 2 randomised clinical trial will investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy.



ACTRN/NCT /ethics:


Scientific title:

ENZA-p: A Randomised Phase II Trial Using PSMA as a Therapeutic Agent and Prognostic Indicator in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide (ANZUP 1901)

Sponsor / Cooperative group:

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Trial & Patient Characteristics

Cancer TypeProstate
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2020-08-17
Anticipated End Date2023-06-01

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Phone08 7074 2342
Principal InvestigatorProfessor Hsiang Tan
Recruitment StatusRecruiting